$FEMY

FEMASYS INC (FEMY) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Femasys Appoints John Moorhead to Board of Directors ATLANTA – October 30, 2026 – Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of ca

Femasys Inc. (FEMY) has appointed John Moorhead to its Board of Directors. This move is tied to a private placement agreement from August 2026. The company is focusing on commercializing FemaSeed and advancing FemBloc toward FDA approval.

Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.

Femasys Inc. (FEMY) has partnered with SandsRx Pharmacy to support the rollout of its FemaSeed fertility portfolio, offering medication coordination and preferred pricing for OB/GYNs. This collaboration is an early commercialization step for FemaSeed, according to the company.

Femasys Inc. (FEMY) has doubled U.S. sites in its FemBloc FINALE pivotal trial to 12, adding Baylor Research Institute and Columbia University Medical Center. The trial is for a non-surgical permanent birth control device, following prior ex-U.S. approvals.

Femasys Inc. (FEMY) announced that Minnesota Women's Care will use its FemVue fertility diagnostic and FemaSeed Complete treatment across all four locations. The adoption follows Femasys' August financing, aimed at expanding its commercial team and OB/GYN adoption. The company's stock closed at $2.67 on Monday, up to $2.81 in pre-market trading.

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

Femasys (FEMY) announced FDA approval of its modular PMA pathway for FemBloc, a non-surgical permanent birth control. The approach allows early review of key components. FemBloc is in the FINALE trial for U.S. approval. FEMY stock rose 35.45% in premarket trading.

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

Mifek Jeffrey Gerald (Chief Clinical-Medical Affairs) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.